** Shares of Janux Therapeutics JANX.O rise 67.5% to $67.34 premarket
** Data from early-stage trial shows all 16 patients with a type of prostate cancer that used co's experimental drug JANX007 achieved declines in levels of prostate-specific antigens
** Drug also had "well-tolerated safety profile" and "maximum tolerable dose has not yet been reached"
** Co selects 2 once-weekly dose regimens when expanding early-stage trial based on results
** BTIG analyst Justin Zelin said investor concerns were expectations may have been too high ahead of the results, but JANX's data exceeded expectations and was "unprecedented"
** Brokerage raises PT to Street-high of $100 from $82
** 12 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $70 - LSEG
** As of last close, stock had risen 274.5% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.